In a groundbreaking first, psilocybin is entering gastroenterology. Dr. Erin Mauney leads a pioneering study exploring how psychedelic therapy could transform treatment for millions suffering from treatment-resistant Irritable Bowel Syndrome, offering new hope for gut-brain disorders.
Roxane Feller, AnimalhealthEurope Secretary-General, tells us all about the new EU rules on veterinary medicines to support more responsible use of antibiotics.
The U.S. Food and Drug Administration (FDA) has given authorisation for the Pfizer/BioNTech COVID-19 booster vaccine to be administered to people aged 65 and over.
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.
Lauren Matelski, Jeremy MacMahon, and Pamela J. Lein from the University of California, Davis, weigh the risks associated with COVID-19 vaccines versus the benefits.
Aarthi JanakiRaman, Research Director, Chemicals and Advanced Materials at TechVision, Frost & Sullivan, explains how glycoscience offers opportunities galore in healthcare.
